Spots Global Cancer Trial Database for Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Official Title: A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.
Study ID: NCT00281528
Study Description
Brief Summary: This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bevacizumab.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Division of Hematology/Oncology University of Alabama at Birmingham, Birmingham, Alabama, United States
Little Rock Hematology Oncology Associates, Little Rock, Arkansas, United States
California Oncology of the Central Valley, Fresno, California, United States
Glendale Memorial Hospital & Health Center, Glendale, California, United States
Front Range Cancer Specialists, Fort Collins, Colorado, United States
Oncology Associates of Bridgeport, Bridgeport, Connecticut, United States
Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States
Memorial Cancer Institute/Breast Cancer Center, Hollywood, Florida, United States
Florida Cancer Institute, Hudson, Florida, United States
Hematology Oncology Associates, Lake Worth, Florida, United States
Medical Specialist of the Palm Beaches, Inc, Lake Worth, Florida, United States
Gulfcoast Oncology Associates, Saint Petersburg, Florida, United States
Peachtree Hematology & Oncology Associates, Atlanta, Georgia, United States
Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States
Center of Hope for Cancers and Blood, Stockbridge, Georgia, United States
Maine Center for Cancer Medicine & Blood Disorders, Scarborough, Maine, United States
Greater Baltimore Medical Center, Baltimore, Maryland, United States
Harbor View Cancer Center, Baltimore, Maryland, United States
Boston Medical Center Moakley Building, Solomont Center for Hematology & Medical Oncology, Boston, Massachusetts, United States
North Shore Medical Cancer Center, Peabody, Massachusetts, United States
St. John's Mercy Medical Center, Saint Louis, Missouri, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
Drs. Forte, Schleidere, & Attas, PA, Englewood, New Jersey, United States
Saint Barnabas Medical Center, Livingston, New Jersey, United States
Monmouth Medical Center, Long Branch, New Jersey, United States
Rosewell Park Cancer Institute Elm & Carlton Carlton Building, Buffalo, New York, United States
Beth Israel Comprehensive Cancer Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
NYU Clinical Cancer Center, New York, New York, United States
Marion L. Shepard Cancer Center, Washington, North Carolina, United States
Medical Oncology Aultman Hospital, Canton, Ohio, United States
Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States
Abington Hematology Oncology, Willow Grove, Pennsylvania, United States
Family Cancer Center, Collierville, Tennessee, United States
Tennessee Cancer Specialists, Knoxville, Tennessee, United States
TX Oncology, PA, Austin, Texas, United States
South Texas Oncology & Hematology Clinical Research Dept., San Antonio, Texas, United States
Virginia Commonwealth University Medical Oncology, Richmond, Virginia, United States
Swedish Cancer Institute, Seattle, Washington, United States
Metropolitan Oncology Center, San Juan, , Puerto Rico
Contact Details
Name: Andrew Seidman, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
